

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 (Original). A method of inducing or accelerating a healing process of a skin wound, the method comprising the step of administering to the skin wound a therapeutically effective amount of insulin and at least one additional agent acting in synergy with said insulin to induce or accelerate the healing process of the skin wound.

Claims 2-3. (Canceled)

4 (Currently Amended). The method of claim ~~4~~ 112, wherein said ~~at least one additional agent~~ growth factor is selected from the group consisting of a platelet-derived growth factor (PDGF), EGF, TGF β , KGF, ECGF and IGF1.

5 (Original). The method of claim 1, wherein said at least one additional agent is a PKC- α inhibitor.

6 (Original). The method of claim 1, wherein said wound is selected from the group consisting of an ulcer, a burn, a laceration and a surgical incision.

7 (Original). The method of claim 6, wherein said ulcer is a diabetic ulcer.

8 (Currently Amended). The method of claim 1,
wherein said insulin is a recombinant insulin.

9 (Original). The method of claim 1, wherein said
insulin is of a natural source.

10 (Currently Amended). The method of claim 1,
wherein said insulin and said at least one additional agent
are contained in a pharmaceutical composition adapted for
topical application.

11 (Original). The method of claim 10, wherein said
pharmaceutical composition is selected from the group
consisting of an aqueous solution, a gel, a cream, a paste, a
lotion, a spray, a suspension, a powder, a dispersion, a salve
and an ointment.

12 (Original). The method of claim 10, wherein said
pharmaceutical composition includes a solid support.

Claims 13-40 (Canceled).

41 (Currently Amended). A pharmaceutical
composition for inducing or accelerating a healing process of
a skin wound, the pharmaceutical composition comprising, as an
active ingredient, a therapeutically effective amount of
insulin and at least one additional agent acting in synergy
with said insulin to induce or accelerate the healing process

| of a skin wound, and a pharmaceutically acceptable carrier
being designed for topical application of the pharmaceutical
composition.

42 (Original). The pharmaceutical composition of
claim 41, wherein said at least one additional agent is a
growth factor.

43 (Currently Amended). The pharmaceutical
composition of claim 42, wherein said growth factor is
| selected from the group consisting of a platelet-derived
growth factor (PDGF), EGF, TGF β , KGF, ECGF and IGF1.

44 (Original). The pharmaceutical composition of
claim 41, wherein said at least one additional agent is a PKC-
 α inhibitor.

45 (Currently Amended). The pharmaceutical
composition of claim 41, wherein said insulin is a recombinant
| insulin.

46 (Original). The pharmaceutical composition of
claim 41, wherein said insulin is of a natural source.

47 (Original). The pharmaceutical composition of
claim 41, wherein said wound is selected from the group
consisting of an ulcer, a burn, a laceration and a surgical
incision.

48 (Currently Amended). The pharmaceutical composition of claim ~~41~~ 47, wherein said ulcer is a diabetic ulcer.

49 (Currently Amended). The pharmaceutical composition of claim 41, wherein said insulin and said at least one additional agent is contained in a formulation adapted for topical application.

50 (Original). The pharmaceutical composition of claim 49, wherein said formulation is selected from the group consisting of an aqueous solution, a gel, a cream, a paste, a lotion, a spray, a suspension, a powder, a dispersion, a salve and an ointment.

51 (Original). The pharmaceutical composition of claim 50, wherein said pharmaceutical composition includes a solid support.

Claims 52-111 (Canceled).

112 (New). The method of claim 1, wherein said at least one additional agent is a growth factor.